loading
Apellis Pharmaceuticals Inc stock is traded at $30.02, with a volume of 653.01K. It is down -0.03% in the last 24 hours and up +32.63% over the past month. Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$30.05
Open:
$30.24
24h Volume:
653.01K
Relative Volume:
0.27
Market Cap:
$3.79B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-14.79
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+6.75%
1M Performance:
+32.63%
6M Performance:
+64.96%
1Y Performance:
+9.60%
1-Day Range:
Value
$29.53
$30.24
1-Week Range:
Value
$28.05
$30.48
52-Week Range:
Value
$16.10
$35.72

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Name
Apellis Pharmaceuticals Inc
Name
Phone
617-977-5700
Name
Address
100 FIFTH AVENUE, WALTHAM, KY
Name
Employee
710
Name
Twitter
@ApellisPharma
Name
Next Earnings Date
2024-12-05
Name
Latest SEC Filings
Name
APLS's Discussions on Twitter

Compare APLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
30.03 3.80B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.18 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
657.20 69.37B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
476.82 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
836.50 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
165.53 34.94B 398.11M -1.03B -868.57M -5.7032

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-15-25 Initiated Wells Fargo Overweight
Sep-26-25 Downgrade Goldman Neutral → Sell
May-09-25 Downgrade BofA Securities Buy → Neutral
May-09-25 Downgrade Raymond James Strong Buy → Outperform
Apr-29-25 Initiated Cantor Fitzgerald Overweight
Dec-17-24 Downgrade Goldman Buy → Neutral
Nov-21-24 Initiated Morgan Stanley Equal-Weight
Oct-25-24 Initiated RBC Capital Mkts Sector Perform
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-16-24 Initiated William Blair Outperform
May-31-24 Initiated Piper Sandler Neutral
Feb-05-24 Upgrade Jefferies Hold → Buy
Dec-14-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-09-23 Initiated Goldman Buy
Nov-02-23 Initiated Mizuho Neutral
Oct-06-23 Upgrade JP Morgan Neutral → Overweight
Sep-15-23 Upgrade Wells Fargo Equal Weight → Overweight
Aug-29-23 Reiterated Citigroup Buy
Aug-03-23 Downgrade JP Morgan Overweight → Neutral
Aug-01-23 Downgrade BofA Securities Buy → Neutral
Jan-03-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-10-22 Downgrade Jefferies Buy → Hold
Jul-19-22 Initiated H.C. Wainwright Buy
Jun-17-22 Resumed Stifel Buy
Apr-14-22 Downgrade ROTH Capital Neutral → Sell
Dec-08-21 Initiated Wells Fargo Overweight
Nov-29-21 Downgrade ROTH Capital Buy → Neutral
Sep-10-21 Reiterated BMO Capital Markets Outperform
Sep-10-21 Reiterated Credit Suisse Neutral
Sep-10-21 Reiterated Needham Buy
Sep-10-21 Reiterated Oppenheimer Outperform
Sep-10-21 Downgrade Wedbush Outperform → Neutral
Aug-19-21 Initiated Jefferies Buy
Aug-19-21 Upgrade Wedbush Neutral → Outperform
May-21-21 Initiated UBS Buy
Apr-16-21 Initiated Goldman Buy
Nov-19-20 Initiated Needham Buy
Sep-01-20 Initiated Stifel Buy
Jul-20-20 Initiated ROTH Capital Buy
Jun-17-20 Initiated BTIG Research Neutral
Apr-01-20 Initiated Raymond James Strong Buy
Mar-31-20 Initiated BMO Capital Markets Outperform
Mar-11-20 Upgrade Wedbush Underperform → Neutral
Jan-07-20 Initiated SVB Leerink Mkt Perform
Dec-19-19 Initiated BofA/Merrill Buy
Nov-22-19 Initiated Wedbush Underperform
Nov-05-19 Initiated Credit Suisse Neutral
Aug-01-19 Reiterated Cantor Fitzgerald Overweight
Jul-12-19 Upgrade JP Morgan Neutral → Overweight
Mar-29-19 Initiated Robert W. Baird Outperform
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Jul-30-18 Upgrade B. Riley FBR Neutral → Buy
May-24-18 Initiated Cantor Fitzgerald Overweight
Apr-12-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Feb-08-18 Initiated B. Riley FBR, Inc. Buy
View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

pulisher
09:07 AM

Earnings To Watch: Apellis Pharmaceuticals Inc (APLS) Reports Q3 2025 Result - GuruFocus

09:07 AM
pulisher
06:59 AM

Apellis Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Movers & Reliable Entry Point Alerts - newser.com

06:59 AM
pulisher
03:11 AM

Published on: 2025-10-29 02:11:34 - newser.com

03:11 AM
pulisher
01:55 AM

How moving averages guide Apellis Pharmaceuticals Inc. tradingJuly 2025 Pullbacks & Capital Protection Trading Alerts - newser.com

01:55 AM
pulisher
Oct 28, 2025

Why retail investors favor Apellis Pharmaceuticals Inc. stockJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

Apellis Pharmaceuticals Inc. stock prediction for this weekQuarterly Profit Summary & Long-Term Capital Growth Ideas - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will a bounce in Apellis Pharmaceuticals Inc. offer an exitWeekly Gains Summary & Safe Entry Point Identification - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Apellis Pharmaceuticals Inc. stock attractive for income investorsEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will breakout in Apellis Pharmaceuticals Inc. lead to full recoveryLong Setup & Detailed Earnings Play Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Regression analysis insights on Apellis Pharmaceuticals Inc. performancePortfolio Return Report & Entry and Exit Point Strategies - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueQuarterly Performance Summary & Technical Entry and Exit Tips - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

What valuation ratios show for Apellis Pharmaceuticals Inc. (1JK) stockMarket Performance Recap & Advanced Technical Signal Analysis - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Apellis Pharmaceuticals Inc. (1JK) stock rise with strong economyWeekly Gains Report & AI Powered Market Trend Analysis - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Apellis Pharmaceuticals Inc. stock maintain dividend yieldJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

Real time scanner hits for Apellis Pharmaceuticals Inc. explainedWeekly Trade Report & High Yield Equity Trading Tips - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

What high frequency data says about Apellis Pharmaceuticals Inc.Market Risk Analysis & Consistent Return Strategy Ideas - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Can Apellis Pharmaceuticals Inc. (1JK) stock survive global slowdownQuarterly Trade Summary & Verified Entry Point Signals - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How sentiment analysis helps forecast Apellis Pharmaceuticals Inc.Quarterly Profit Review & Step-by-Step Trade Execution Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Can Apellis Pharmaceuticals Inc. stock sustain market leadership2025 Market Outlook & Weekly Breakout Watchlists - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

How Apellis Pharmaceuticals Inc. stock performs in weak economyMarket Growth Summary & Breakout Confirmation Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will Apellis Pharmaceuticals Inc. stock gain from lower inflation2025 Price Targets & Reliable Breakout Stock Forecasts - newser.com

Oct 27, 2025

Apellis Pharmaceuticals Inc Stock (APLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Apellis Pharmaceuticals Inc Stock (APLS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Sullivan Timothy Eugene
Chief Financial Officer
Oct 21 '25
Sale
28.03
10,000
280,300
110,936
$36.97
price up icon 1.48%
$89.75
price down icon 2.11%
$29.11
price down icon 0.09%
$105.14
price up icon 0.09%
biotechnology ONC
$314.42
price down icon 0.53%
$165.69
price up icon 0.24%
Cap:     |  Volume (24h):